Our latest press releases, media appearances and news commentary.
The Alderley Park facility received the award for its integral role in establishing the Lighthouse Laboratory network.
The UK’s centre for therapeutics innovation, Medicines Discovery Catapult (MDC), has received a £5 million grant to build a Translational Research Facility in Infectious Disease on its Alderley Park site.
Chris Molloy, Chief Executive Officer of the Medicines Discovery Catapult will be stepping down in September 2021 after five years in the role.
Psychiatric drug discovery must be a truly collaborative process if it is to be successful.
While student perceptions of careers in science may come with a lack of diversity, the Covid-19 pandemic has highlighted the important contributions made by scientists and healthcare professionals…
Medicines Discovery Catapult’s newly appointed Chief Business Officer, Dr Nicola Heron MBA sets out her intention to support up-and-coming innovators…
Ahead Of International Day Of Women And Girls In Science, Three Covid Scientists Share Their Experience of Battling the Pandemic.
Staff and students at the University of Manchester have been recognised for their role in helping to establish the Alderley Park Lighthouse Laboratory in Cheshire.
A partnership between the University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.
Scientists at the Alderley Park Lighthouse Lab in Cheshire have revealed the speed and scale at which the new variant of the COVID virus is spreading through communities across the country.
See how we can help support you with your next drug discovery project.
Speak to us